tbuckley/cabot-search huggingface dataset:
Abstract 2895: The epithelial to mesenchymal transition is associated with alterations in the mitogenic signaling pathways that drive cancer cell proliferation
Authors: Patrick E. Corsino, Mary Law, Stephan Jahn, Brad Davis, Brian Law
Journal: Cancer Research (2011)

Abstract The Epithelial to Mesenchymal Transition (EMT), by facilitating the metastatic process, is an important step in tumor progression for many types of cancer. We have developed a mouse tumor model, driven by the HER2/neu oncogene, whereby this process can be studied robustly both in vivo and in cell culture. This system has revealed significant changes in mitogenic signaling networks that occur during EMT. Post-EMT cancer cells acquired increased responsiveness to HGF, PDGF, and LPA. This change in responsiveness was accompanied by a decrease of Her2, c-Src and IRS-1 levels, as well as an increase in Axl, PDGFR and c-Met levels. Perturbations in these signaling cascades results in the differential sensitivity to certain anti-cancer therapeutics. Post-EMT cells were less sensitive than Pre-EMT cells to the MEK inhibitor U0126. Furthermore, while Pre-EMT cells exhibited cell cycle arrest in response to rapamycin, Post-EMT cell proliferation was stimulated. These observations may have significant bearing on the efficacy of targeted therapeutic agents in patients with metastatic breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2895. doi:10.1158/1538-7445.AM2011-2895
CIRCULATING PENTRAXIN 3 LEVELS WERE ASSOCIATED WITH CORONARY PLAQUE COMPOSITIONS ASSESSED BY IMAP-INTRAVASCULAR ULTRASOUND
Authors: Seiji Koga, Satoshi Ikeda, Miyuki Eto, Takeo Yoshida, Tomoo Nakata, Yuji Koide, Hiroaki Kawano, Koji Maemura
Journal: Journal of the American College of Cardiology (2014)
Abstract P2-05-07: Comparison of hormone receptor and HER-2 expression in primary breast cancers and sentinel lymph node metastases
Authors: N Rokutanda, J Horiguchi, D Takata, R Nagaoka, A Sato, H Tokiniwa, K Tozuka, S Uchida, I Takeyoshi
Journal: Cancer Research (2012)

Abstract Background: Recently, it is a hot topic that the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER2) may differ between the primary tumors and the paired recurrent metastatic tumors. On the other hand, the concordance of the ER, PR, and HER2 status between the primary tumor and ipsilateral axillary lymph node metastases is reported to be high in previous study. However, in these reports, the majority of lymph nodes metastases examined are macrometastases obtained from axillary lymph node dissection. The aim of the present study is to compare the ER, PR, and HER2 status of the primary breast tumors with that of sentinel lymph node micrometastases and macrometastases. Methods: A total of 770 breast cancer patients underwent sentinel lymph node biopsy between 2006 and 2010 at our hospital. Among them, 87 patients who had only one node positive were eligible for our study. ER, PR, and HER2 status were determined by immunohistochemistry (IHC) and/or FISH. Result: We analyzed 76 patients with 50(66%) patients with macrometastasesn and 26 (34%) micrometastases, except 11 cases those were indeterminate for IHC. ER status of primary tumor and the paired metastatic lymph node were almost full concordance except one case, in which ER was negative in primary tumor but ER was positive in lymph node. Discordance for PR was 15.8% (n = 12). Among these, six patients had PR-positive on primary and PR-negative in lymph node while six patients had PR-negative in primary and PR-positive in lymph node. Discordance for HER2 between primary tumor and metastatic lymph node was 5.3% (n = 4). Among these, three had negative in primaries and positive in lymph nodes while one had positive in primary and negative in lymph node. A discordance between primary and lymph node in HER2, ER, or PR status was observed in 14 of 67 (18.4%) cases. Conclusions: The concordance in HER2, ER, and PR was high between the primary tumor and sentinel lymph nodes. However some cases had discordance of receptor status and these result may cause of discordance for distant metastases or poor prognosis. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-05-07.
Abstract 4945: Androgen-mediated phenotypic change produces a miRNA fingerprint in prostate carcinoma cells
Authors: Corrinne V. Segal, Christopher J. Powell, Nigel J. Gooderham
Journal: Cancer Research (2011)

Abstract Activation of the androgen receptor (AR) results in phenotypic change in androgen-responsive cells; for example, in the human prostate carcinoma cell line (LNCaP) androgens mediate cell proliferation. Factors controlling the range of phenotypic responses mediated by androgens are only partially understood, but include both transcriptional and post-transcriptional mechanisms. One such mechanism that appears to offer wide ranging, yet highly selective control, is microRNA-mediated post-transcriptional regulation. In the present study, we assessed the influence of endocrine-active compounds that act via the AR pathway on the microRNA (miRNA) profile. As negative regulators of gene expression, miRNA are short non-coding RNA that are able to suppress translation or induce degradation of their target mRNA transcripts leading to decreased protein expression. The effect of exposure of LNCaP cells to a model synthetic AR agonist, a physiological androgen and a therapeutic AR antagonist was determined at various time points up to 120 hours. Phenotypic response to exposure was assessed as an alteration of proliferative ability, expression of prostate-specific antigen (PSA) and alteration of the miRNA-ome. As expected, the agonists significantly induced proliferation and PSA expression, compared to vehicle control, whilst the antagonist itself had no effect on proliferation and PSA expression except when cultured in the presence of the natural ligand resulting in potentiation of the ligand's effects. The temporal effects of the compounds on the expression profile of 866 miRNAs were assessed using Agilent's miRNA microarray version 3. A number of miRNAs were found to be altered in a compound-specific and temporal manner, including some implicated in cell cycle control. qRT-PCR of select miRNAs proceeded to validate the fold changes observed by microarray. Targets for altered miRNAs were deduced using bio-informatic approaches and immunoblotting of target proteins has confirmed that protein levels are inversely correlated. These data describe an androgen-mediated miRNA ‘fingerprint’ that is compound and temporally dependent and provides mechanistic insights into the biological responses of cells to such compounds. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4945. doi:10.1158/1538-7445.AM2011-4945
Case 33-1992
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, N.M. Heney, F.J. McGovern
Journal: New England Journal of Medicine (1992)

Presentation of CaseA 34-year-old woman was admitted to the hospital because of low-back and flank pain, with oliguria.The patient was well until seven years earlier, when severe abdominal pain developed, and a laparotomy performed at another hospital revealed endometriosis with intraperitoneal bleeding from the right ovary; a right oophorectomy was performed. Thereafter, the patient experienced chronic abdominal pain. Three years before entry abdominal adhesions were lysed at a second hospital. Eighteen months before admission leuprolide acetate was prescribed and was continued for 16 months. Eight months before admission evidence of Graves' disease was found; atenolol was prescribed, and . . .
P236 Relationship Between Bone Mineral Density And Bone Turnover Markers In Severe Asthma Patients On Systemic Corticosteroids
Authors: H. Brice, J. Farrant, S. Fowler, L. Holmes, J. Tang, C. Washbourne, I. Piec, W. Fraser, J. Sweeney, L. Heaney, R. Niven
Journal: Thorax (2014)

<h3>Objectives</h3> Measure bone turnover markers (BTM) CTx, P1NP and bone-specific alkaline phosphatase (BsALP) in a severe asthma population using systemic corticosteroids (SCS). Assess bone mineral density (BMD) change in regional severe asthma clinics. <h3>Background</h3> Severe asthma often requires regular SCS use. SCS cause several adverse effects including reduced bone metabolism; resorption is increased and formation is decreased resulting in osteoporosis. DXA scans monitor BMD in the hip and spine every 3–5 years. BMD decrease is treated with bone sparing medication (BSM), but treatment is retrospective and response takes years to assess. BTM represent markers of systemic bone metabolism and may offer a more efficient alternative. CTx is a resorption marker, P1NP and BsALP are formation markers. <h3>Method</h3> Patients attending Manchester or Belfast severe asthma clinic with two or more DXA scans were identified from case files. We measured BTM in Manchester severe asthma patients and a control group of Manchester severe asthma patients requiring less than 3 courses of steroids per year. Using case files we collected data including DXA scan results, SCS use and osteoporosis risk factors. <h3>Results</h3> BMD change and BTM did not correlate overall (patients n = 78, controls n = 18) but correlated negatively in patients where the most recent DXA was <h3>Conclusion</h3> This study has confirmed that BTM may be potentially used as a surrogate for BMD measurement; however a more a prospective study where BTM are measured at the time of two DXA scans which are years apart is required.
SAT0125 Who are the Patients with Rheumatoid Arthritis with “Worse than Death” Scores on the Eq-5D? Results from the Comedra Study: Table 1
Authors: C. Gaujoux-Viala, A.-C. Rat, F. Guillemin, A. Etcheto, M. Dougados, B. Fautrel
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Indirect utility measures are increasingly used to assess health benefits in RCTs and to estimate Quality-adjusted life-years (QALYs) gain in cost-effectiveness models. The EQ-5D is a 5-dimensional multi-attribute questionnaire widely used to calculate QALY. It allows negative utility values which theoretically correspond to health state “worse than death”9. <h3>Objectives</h3> To analyse the patients reporting EQ-5D &lt;0 ie in states theoretically labeled “worse than death” and to investigate their health status in a large multicenter trial of patients with rheumatoid arthritis (RA). <h3>Methods</h3> EQ-5D measures were assessed in 962 patients of COMEDRA, a national multicentric clinical trial involving patients with stable RA. Clinical outcomes and laboratory measures were also recorded (activity by DAS28, function by HAQ score, Rheumatoid Arthritis Impact of Disease score ...). The characteristics and health status of patients with an EQ-5D&lt;0 were analyzed. Multivariate logistic regression was used to determine which specific aspects of RA were independently associated with states worse than death. <h3>Results</h3> At baseline, 38 (4%) patients were in states worse than death. Mean EQ-5D values were -0.073±0.092 (range -0.416 to -0.017). Almost all patients reported moderate problems in mobility, in usual activities, and in self-care. Concerning other domains, 55.3% of patients reported severe anxiety/depression and 44.7% moderate anxiety/depression; 55.3% reported extreme pain/discomfort and 44.7% moderate pain/discomfort. Patients with negative EQ-5D scores had higher disease activity, higher HAQ score, more pain, more fatigue, lower mental component of the RAID, more difficulties in coping and higher CRP than patients with EQ-5D≥0 (all p&lt;0.01). In the logistic regression model, increasing HAQ score, decreasing coping, increasing physician global assessment and increasing fatigue were associated with negative EQ-5D scores (Table 1). <h3>Conclusions</h3> HAQ and coping were the main determinants of state worse than death. These results highlight the importance of taking into account patients coping strategies, functional abilities and fatigue to better care for patients and to improve their adaptation to their disease. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5761
EZH2, Proliferation Rate, and Aggressive Tumor Subtypes in Cutaneous Basal Cell Carcinoma
Authors: Rajesh C. Rao, May P. Chan, Christopher A. Andrews, Alon Kahana
Journal: JAMA Oncology (2016)

Basal cell carcinoma (BCC) is the most common human malignancy.Although precise data are not available, nonmelanoma skin cancer, of which approximately 80% are BCCs, is estimated to affect 2 to 3.5 million Americans annually. 1While most sporadic BCCs are treated with excision or other destructive modalities, treatment of locally advanced BCC on the face, hands, feet, and genitals can lead to significant morbidity.Although rare, patients with basal cell nevus (Gorlin) syndrome have numerous BCCs that are difficult to control surgically, and metastatic BCC carries a poor prognosis.For individuals with locally advanced BCC or metastatic BCC, hedgehog signaling pathway inhibitors (vismodegib and sonidegib) constitute the only US Food and Drug Administration-approved medical treatment. 2,3In phase 2 trials, these inhibitors were associated with a 15% to 58% response rate and 14% to 30% serious adverse event rate. 2,3Identification of markers for aggressive BCC histology could provide tools for predicting and assessing treatment response or may themselves represent actionable targets.EZH2 is a histone methyltransferase of the polycomb repressive complex 2 that is activated in medulloblastoma, a malignancy that, like BCC, is associated with hedgehog pathway signaling. 4,5 To assess whether EZH2 is a marker for more aggressive BCCs, we compared more vs less histologically aggressive BCCs for expression of EZH2 and Ki67, a marker of proliferation linked to EZH2, using an index that has been used to risk-stratify patients with other cancers. 6
Abstract 5383: Cucurbitacin B, a novel <i>in vivo</i> potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer
Authors: Gabriela B. Iwanski, Nils H. Thoennissen, Dhong Hyung Tony Lee, Ngan B. Doan, Brandon Castor, Alison Le, Melvin Toh, Carsten Bokemeyer, Jonathan W. Said, H. Phillip Koeffler
Journal: Cancer Research (2010)

Abstract Pancreatic cancer is a highly aggressive malignancy, and improvement in systemic therapy is necessary to treat this frequently encountered metastatic disease. The current targeted agents used in combination with gemcitabine improved objective response rates, but with little or no improvements in survival and also increased toxicities in pancreatic cancer patients. Recently, we showed that the triterpenoid cucurbitacin B inhibited tumor growth in pancreatic cancer cells by inhibition of the JAK/STAT pathway, and synergistically increased antiproliferative effects of gemcitabine in vitro. The anti-tumor and toxicity effects of cucurbitacin B in combination with gemcitabine were tested against human pancreatic cancer cells in a murine xenograft model. The combinatory therapy of cucurbitacin B and gemcitabine at relatively low doses (0.5 mg/kg and 25 mg/kg, respectively) resulted in highly significant tumor growth inhibition of pancreatic cancer xenografts by up to 79% (p&amp;lt;0.001). Remarkably, this therapy was well tolerated by the animals, including histology of inner organs, analysis of serum chemistries, full blood counts, and bone marrow colony numbers. Western blot analysis of the tumor samples of mice who received both agents, cucurbitacin B and gemcitabine, revealed stronger inhibition of Bcl-XL, Bcl-2 and c-myc, and higher activation of the caspase-cascades compared to single agent treated mice. The in vivo combination therapy of cucurbitacin B and gemcitabine has profound antiproliferative effects against human pancreatic cancer cells, without any significant signs of toxicity. This promising combination should be examined in therapeutic trials of pancreatic cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5383.
Randomized Trial of Allopurinol in the Prevention of Calcium Oxalate Calculi
Authors: Bruce Ettinger, Anne Tang, John T. Citron, Barbara Livermore, Thomas Williams
Journal: New England Journal of Medicine (1986)

In a double-blind study, we examined the efficacy of allopurinol in the prevention of recurrent calcium oxalate calculi of the kidney. Sixty patients with hyperuricosuria and normocalciuria who had a history of calculi were randomly assigned to receive either allopurinol (100 mg three times daily) or a placebo. After the study, the placebo group had 63.4 percent fewer calculi (P<0.001), whereas the allopurinol group had 81.2 percent fewer calculi (P<0.001). During the study period, the mean rate of calculous events was 0.26 per patient per year in the placebo group and 0.12 in the allopurinol group. When the treatment groups were compared by actuarial analysis, the allopurinol group was found to have a significantly longer time before recurrence of calculi (P<0.02). We conclude that allopurinol is effective in the prevention of calcium oxalate stones in patients with hyperuricosuria. The large reduction in the frequency of calculi in the placebo group underscores the positive treatment bias that regularly occurs in trials of prophylaxis against renal calculi when historical controls are used. (N Engl J Med 1986; 315:1386–9.)
Abdominal lymphocele misdiagnosed as pancreatic cystic lesion, report of two cases. EUS features, accuracy, safety and role of preoperative FNA
Authors: G Perez Alvarez
Journal: Endoscopy (2011)

We present two cases of diagnosis of abdominal lymphocele by means of EUS features and FNA results, previously misdiagnosed as pancreatic cystic lesions at the imaging studies. The first case is a 58 year-old female that has been studied for a mild abdominal pain and a uterine mioma. An abdominal ultrasound showed a peripancreatic hypoecoic lesion compatible with pathologic lymph node. Then an MDCT was performed, concluding that the lymph node was actually a cystic lesion emerging from the pancreas, not ruling out a pancreatic cystic neoplasia. The linear EUS showed an anechoich lesion clearly extrinsec from the pancreatic body, whit fine septa and no solid component. A single pass FNA was performed with a 22G needle across a very elastic capsule, obtaning 2ml of white fluid. CEA and CA 19.9 levels were normal, meanwhile a very high trygliceride (3663mg/dL) and amylase (240 U/L) levels were detected. The cytology specimen didn? t showed malignancy.
AB0208 Prevalence of anemia and its relationship with disease activity in patients with rheumatoid arthritis: quest-ra study in morocco.
Authors: A. Hari, S. Rostom, R. Lahlou, B. Benchekroun, L. Benbrahim, R. Bahiri, N. Hajjaj Hassouni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate the prevalence of anemia in patients with rheumatoid arthritis and analyze its relationship with parameters of disease activity from the QUEST-RA data Moroccan. <h3>Methods</h3> Moroccan QUEST-RA (Quantitative Standard Monitoring Patients with Rheumatoid Arthritis), inspired from Finnish QUEST-RA. Moroccan QUEST-RAis a national multicentric cross-sectional study of patients with rheumatoid arthritis (according to the 1987 ACR criteria) enrolled in public and private sectors, over a period from January 2008 to December 2010. Pre-established questionnaire containing sociodemographic, clinical and paraclinical characteristics was completed by all patients. Patients were divided into two groups: a group with anemia (hemoglobin &lt;13 g / dl in men, &lt;12g/dl in women) and a group without anemia (hemoglobin ≥ 13g/dl in women and ≥ 12g/dl humans) according to the criteria of the World Health Organization. The parameters of disease activity were assessed by EVA patient, EVA doctor, erythrocyte sedimentation rate (ESR), C- Reactive protein (CRP) and DAS-28 ESR. <h3>Results</h3> 1129 patients with RA were eligible. The mean age of patients was 48.8 ± 12.7 years with female predominance (87.3%). The median disease duration was 6 years (3-12), the mean DAS28 ESR was 4.94 ± 1.68, the median HAQ was 1 (0.37-1.62). The prevalence of anemia was 28.8%. In univariate analysis, there was a significant association between the presence of anemia, ESR, CRP, HAQ with respectively [(OR = 1.20, 95% CI (1.01-1.40)) (OR = 1.02, 95% CI (1.01 to 1.04)) (OR = 2.07, 95% CI (1.74 to 3.47)) (for all p &lt;0.05)]. Moreover, there was no association between anemia and the presence of comorbidities (ulcer; IDM, vascular pathology ….). In multivariate analysis, only persist an association between anemia, ESR (OR = 1.02, 95% CI (1.01 to 1.06)) and HAQ (OR = 1.04, 95% CI (1.01 to 1.60)) for all p &lt;0.05. <h3>Conclusions</h3> This study suggests that the prevalence of anemia was common and appeared to be independently associated with disease activity. Further studies are needed. <h3>Acknowledgements</h3> Dr Samir Ahid: Laboratory of Biostatistics, Clinical Research and Epidemiology, Faculty of Medicine and Pharmacy. Rabat. Morocco. <h3>Disclosure of Interest</h3> None Declared
Abstract 2454: Pancreatic cancer stem cells (CSCs) express MUC1 and MUC1-expressing pancreatic cancers encompass higher levels of CSCs
Authors: Jennifer M. Curry, Kyle J. Thompson, Shanti Rao, William A. Ahrens, Iain H. McKillop, David Sindram, David A. Iannitti, John B. Martinie, Pinku Mukherjee
Journal: Cancer Research (2011)

Abstract Introduction: Pancreatic ductal adenocarcinoma (PDA) has the worst prognosis of all cancers and is the fourth leading cause of cancer-related deaths in the United States. Cancer stem cells (CSCs), which are a small population of tumor cells that have the ability to self-renew and differentiate into the diverse cells that comprise the tumor, have been identified in pancreatic cancer patients as lineage-negative, CD133 (prominin-1)-expressing cells. In pancreatic cancer, MUC1 is a protein expressed with a high frequency and its expression correlates with high metastasis and poor prognosis. Recent reports from our lab have demonstrated the ability of MUC1 to drive epithelial-to-mesenchymal transition thus producing a cell with ‘stem-like’ properties. We therefore investigated the correlation between MUC1 expression and CSCs. Methods: Primary tumor tissues surgically resected from patients diagnosed with pancreatic adenocarcinoma (n=8) and human pancreatic cancer cell lines were assessed for CD133 and MUC1 expression by flow cytometry. Results: In pancreatic cancer patients, tumor MUC1 levels correlated with a higher percentage of CD133-expressing cells (R=0.76). Similarly, in MiaPaCa2, Capan-1, BxPC3 WT, BxPC3 MUC1, Su86.86 WT and Su86.86 MUC1 cells lines, MUC1 levels correlated with increased CD133 expression (R=0.83). The majority of CD133+ cells isolated from primary human pancreatic tumors (82.6 ± 12.7%) expressed MUC1. Similar results were obtained using cell lines, as 83.22 ± 30.9% of CD133-expressing cells were MUC1-positive. Conclusion: MUC1 is present on the majority of CSCs and its expression correlates with higher levels of cancer stem cells. This study demonstrates yet another oncogenic role of MUC1 in pancreatic cancer progression and suggests MUC1 as a novel marker for CSCs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2454. doi:10.1158/1538-7445.AM2011-2454